OncoMatch/Clinical Trials/NCT07324304
NWRD06 DNA Plasmid for HCC After Curative Resection.
Is NCT07324304 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies NWRD06 administered by electroporation for hepatocellular carcinoma (hcc).
Treatment: NWRD06 administered by electroporation — This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after curative resection.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Biomarker criteria
Required: GPC3 positive by immunohistochemistry
GPC3 positive confirmed by immunohistochemistry (IHC)
Disease stage
Required: Stage BCLC A, BCLC B, CNLC IB, CNLC IIA, CNLC IIB, CNLC IIIA (BCLC, CNLC)
Barcelona clinic liver cancer (BCLC) stage A/B or Chinese Hepatocellular carcinoma Stage (CNLC) Ib-IIIa
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: curative treatment — surgical resection or local ablation
Must have undergone curative treatment (surgical resection or local ablation) for HCC within 12 weeks prior to the first NWRD06 administration
Cannot have received: systemic anti-tumor therapy
Received any systemic anti-tumor therapy for HCC (including chemotherapy, molecular targeted therapy, bio-immunotherapy) within 28 days prior to screening
Lab requirements
Blood counts
Hemoglobin (Hb) ≥90 g/L; Platelet count (PLT) ≥75×10^9/L
Kidney function
Serum Creatinine (Scr) ≤1.5 × ULN, OR Creatinine Clearance ≥40 mL/min (if Scr >1.5 × ULN)
Liver function
Total bilirubin (TB) ≤3× ULN; ALT and AST ≤5×ULN; Plasma albumin ≥30g/L; Child-Pugh score A/B (≤7)
Adequate organ function within 1 week prior to the first dose: 1) Blood routine: Hemoglobin (Hb) ≥90 g/L; Platelet count (PLT) ≥75×10^9/L; 2) Liver: Total bilirubin (TB) ≤3× ULN; ALT and AST ≤5×ULN; Plasma albumin ≥30g/L; 3) Coagulation: INR ≤2.3. 4) Renal: Serum Creatinine (Scr) ≤1.5 × ULN, OR Creatinine Clearance ≥40 mL/min (if Scr >1.5 × ULN). Child-Pugh score A/B (≤7)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07324304 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anti-tumor therapy disqualifies patients from enrollment.
Does this trial require GPC3?
Yes, GPC3 positive by immunohistochemistry is a required biomarker for enrollment.
What disease stage is eligible?
Stage BCLC A or BCLC B or CNLC IB or CNLC IIA or CNLC IIB or CNLC IIIA is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages